AntiBacFilm: Novel marine biomolecule with antibiofilm activity
Healthcare associated infections related with implants and catheters have a tremendous negative socio-economic impact in our society. AntiBacFilm refers to novel antibacterial and antibiofilm compounds of the lactylate type, isolated from the cyanobacterial strain Sphaerospermopsis sp. LEGE 00249 belonging to LEGEcc. These compounds and their derivatives present antibacterial activity against Staphylococcus aureus and antibiofilm activity against coagulasenegative staphylococci, which are the main agents of infections associated with medical devices.
The antibiofilm activity is of extreme importance because biofilms act as a barrier against the action of therapeutic agents leading to the recalcitrance of this type of infections. A further advantage of this invention is the potential low toxicity and biodegradability of the lactylates, whose application in the food and cosmetic industries is well known. This project aims at the protection through national and international patent of the invention AntiBacFilm that, due to their natural origin, potential biodegradable characteristics and low toxicity, and antibacterial and antibiofilm activities, brings together the ideal characteristics for the development of new products and treatments against medical device-associated infections.
The international patent application will represent a competitive advantage in the search for new economic partners to support the developments needed to take AntiBacFilm to market and to ensure an effective commercialization, stimulating the national competitiveness.